Targeted radionuclide therapy (TRT) is gaining wide and rapid acceptance in clinical practice as it can deliver alpha or beta irradiation to a tumor-associated target which may be present in the tumor cell itself or in the microenvironment [...].
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10969543 | PMC |
| http://dx.doi.org/10.3390/cimb46030152 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preclinical Evaluation of Ga/Lu-Labeled FAP-Targeted Peptide for Tumor Radiopharmaceutical Imaging and Therapy.
J Nucl Med
January 2025
Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China
Fibroblast activation protein (FAP) has been considered a promising target for tumor imaging and therapy. This study designed a novel peptide, FAP-HXN, specifically targeting FAP and exhibiting significant potential as a radionuclide-labeled theranostic agent. Preclinical studies were conducted to evaluate the potency, selectivity, and efficacy of FAP-HXN.
View Article and Find Full Text PDFCross sections of the Ra(p,xn) reactions relevant for Ac production.
Nucl Med Biol
January 2025
Nuclear Physics Institute of the Czech Academy of Sciences, Řež, Czech Republic.
Limited availability constrains the implementation of Ac, the most promising α emitter for targeted therapy, in clinical practice. Proton activation of Ra is one of few realistic solutions to this problem. We have therefore measured cross sections of relevant Ra(p,xn) nuclear reactions in the energy range of 12.
View Article and Find Full Text PDFHarnessing Radionuclides: Unveiling the Promising Role of Radiopharmaceuticals in Cancer Theranostics and Palliative Care.
Curr Radiopharm
January 2025
Apollonia" University of Iasi, Faculty of Dental Medicine, 11 Pacurari Str., 700511, Iasi, Romania.
Background: In the context of modern oncology, radiogenic elements have emerged as pivotal tools for targeted cancer therapies. Elements like Iodine-131 and Yttrium-90 offer unique radiological properties that allow precise treatment delivery. This article explores their growing importance and potential in reshaping the landscape of cancer therapy.
View Article and Find Full Text PDFPretargeted Trop-2 immunoPET for rapid, selective detection of pancreatic tumors.
Clin Cancer Res
January 2025
Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Purpose: Recent clinical advances with the approval of antibody-drug conjugates targeting Trop-2 such as sacituzumab-govitecan and datopotomab-deruxtecan have garnered tremendous interest for their therapeutic efficacy in numerous tumor types including breast and lung cancers. ImmunoPET can stratify tumor avidity, clarifying patient eligibility for ADC therapy as well as a diagnostic companion during therapy. Slow antibody circulation requires days to reach optimal imaging timepoints.
View Article and Find Full Text PDFFuture Directions in the Treatment of Low-Grade Gliomas.
Cancer J
January 2025
Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL.
There is major interest in deintensifying therapy for isocitrate dehydrogenase-mutant low-grade gliomas, including with single-agent cytostatic isocitrate dehydrogenase inhibitors. These efforts need head-to-head comparisons with proven modalities, such as chemoradiotherapy. Ongoing clinical trials now group tumors by intrinsic molecular subtype, rather than classic clinical risk factors.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!